Logo

LNTH

Lantheus Holdings, Inc.

LNTH

Lantheus Holdings, Inc. • NASDAQ
$58.87 ▲ 0.20% (+0.12)
Market Cap $4.03 B
52w High $111.29
52w Low $47.25
Dividend Yield 0%
P/E 24.43
Volume 281.63K
Outstanding Shares 68.40M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $384.014M ▲ $178.751M ▲ $27.771M ▼ 7.232% ▼ $0.41 ▼ $67.739M ▼
Q2-2025 $378.045M ▲ $153.045M ▲ $78.755M ▲ 20.832% ▲ $1.15 ▲ $122.665M ▲
Q1-2025 $372.764M ▼ $135.633M ▲ $72.945M ▲ 19.569% ▲ $1.06 ▲ $114.959M ▲
Q4-2024 $391.11M ▲ $134.673M ▲ $-11.79M ▼ -3.014% ▼ $-0.17 ▼ $21.547M ▼
Q3-2024 $378.734M $108.383M $131.093M 34.613% $1.89 $198.096M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $382.006M ▼ $2.276B ▲ $1.157B ▲ $1.119B ▼
Q2-2025 $695.572M ▼ $2.116B ▲ $949.294M ▲ $1.167B ▲
Q1-2025 $938.533M ▲ $2.055B ▲ $891.03M ▼ $1.164B ▲
Q4-2024 $912.814M ▲ $1.98B ▼ $892.329M ▲ $1.088B ▼
Q3-2024 $866.386M $2.05B $869.922M $1.18B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $27.771M ▼ $105.294M ▲ $-319.468M ▼ $-99.166M ▼ $-313.566M ▼ $94.672M ▲
Q2-2025 $78.755M ▲ $87.106M ▼ $-232.472M ▼ $-98.413M ▼ $-242.952M ▼ $73.732M ▼
Q1-2025 $72.945M ▲ $107.563M ▼ $-63.718M ▼ $-18.219M ▲ $25.728M ▼ $98.845M ▼
Q4-2024 $-11.79M ▼ $155.399M ▼ $-6.602M ▲ $-101.328M ▼ $46.428M ▼ $139.03M ▼
Q3-2024 $131.093M $175.062M $-67.798M $1.869M $109.368M $159.254M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
DEFINITY
DEFINITY
 $90.00M ▲$80.00M ▼$80.00M ▲$80.00M ▲
License and Royalty Revenues
License and Royalty Revenues
 $0 ▲$10.00M ▲$0 ▼$10.00M ▲
Other Precision Diagnostics
Other Precision Diagnostics
 $10.00M ▲$10.00M ▲$10.00M ▲$10.00M ▲
Product
Product
 $390.00M ▲$370.00M ▼$370.00M ▲$380.00M ▲
PYLARIFY
PYLARIFY
 $270.00M ▲$260.00M ▼$250.00M ▼$240.00M ▼
Radiopharmaceutical Oncology
Radiopharmaceutical Oncology
 $270.00M ▲$260.00M ▼$250.00M ▼$240.00M ▼
Strategic Partnerships And Other
Strategic Partnerships And Other
 $10.00M ▲$10.00M ▲$10.00M ▲$10.00M ▲
Techne Lite
Techne Lite
 $30.00M ▲$20.00M ▼$20.00M ▲$20.00M ▲
Total Precision Diagnostics
Total Precision Diagnostics
 $120.00M ▲$100.00M ▼$120.00M ▲$130.00M ▲
Other Radiopharmaceutical Oncology
Other Radiopharmaceutical Oncology
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Revenue has grown very quickly over the past five years, moving the business from a small niche player to a mid‑scale, profitable company. Profitability has improved even faster than sales: gross margins are high, operating profit has swung from losses to solidly positive, and net income has scaled up sharply. Earnings per share are now many times higher than they were a few years ago, although the most recent year shows a slight step down versus the prior year, which could reflect higher taxes, investment spending, or mix shifts. Overall, the income statement shows a company that has successfully commercialized key products and gained operating leverage, but that may be entering a more mature, less “explosive” phase of earnings growth compared with the initial ramp‑up.

Balance Sheet

Balance Sheet The balance sheet has strengthened meaningfully. Total assets and cash holdings have risen steadily, giving the company a sizable liquidity cushion. Debt has not grown in line with assets, so leverage looks more manageable over time, and shareholders’ equity has expanded as retained profits accumulate. This shift from a more debt‑reliant, asset‑light profile to a better‑capitalized position reduces financial risk and gives the company more flexibility for R&D, acquisitions, or downturns. A key watchpoint is that debt is still present and the business remains concentrated in specialized products, so maintaining strong cash generation is important to keep the balance sheet robust.

Cash Flow

Cash Flow Cash flow has improved from barely positive levels to strong, consistently positive operating cash generation. Free cash flow has followed the same path, as investment in physical assets remains modest relative to cash from operations. This pattern suggests the business model is asset‑light and high margin, with ample internal cash to fund research, partnerships, and selective deals without heavy capital spending. The main risks to cash flow are external: reliance on a few flagship products, reimbursement dynamics, and ongoing R&D needs. But as of now, cash flow quality appears solid, and the company is not stretching itself with large capital projects.

Competitive Edge

Competitive Edge Lantheus occupies a strong position in specialized imaging and radiopharmaceuticals, especially in prostate cancer and cardiac imaging. Its flagship products in PSMA PET imaging and ultrasound contrast enjoy leading market shares and strong brand recognition among clinicians. The company’s competitive moat is reinforced by complex manufacturing and logistics for short‑lived radiopharmaceuticals, a broad and integrated distribution network, and deep regulatory experience. These factors make it hard for new entrants to replicate its footprint quickly. At the same time, the niches it serves are attracting more attention from large pharma and imaging players, so defending this lead will likely require sustained innovation, strong relationships with hospitals, and continuous investment in reliability of supply.

Innovation and R&D

Innovation and R&D Innovation is a central pillar for Lantheus. The company has combined advanced imaging agents with artificial intelligence platforms that help doctors interpret scans more consistently and quantitatively. Its AI tools for prostate cancer and bone metastases give it a technology edge and embed its products deeper into clinical workflows. Beyond current blockbusters, the pipeline is broad: new formulations to expand production capacity, radioligand therapies for prostate and neuroendocrine tumors, and next‑generation alpha therapies that could be more potent cancer treatments. The company is also pushing into neurology with diagnostics for Alzheimer’s disease and has used acquisitions to accelerate this effort. This strategy creates multiple avenues for future growth but also raises execution risk, regulatory risk, and integration challenges as the firm stretches from pure diagnostics into more therapeutic “theranostic” territory.

Summary

Lantheus has transformed itself over the past five years into a high‑growth, highly profitable specialist in diagnostic imaging and radiopharmaceuticals. Financially, revenue and profits have scaled rapidly, margins are strong, and cash generation is healthy, which has strengthened the balance sheet and reduced financial risk. Strategically, the company holds leading positions in prostate and cardiac imaging, backed by complex supply chains, AI‑enhanced platforms, and regulatory know‑how that together form a meaningful moat. Its future increasingly depends on continued success of key products and on converting a promising oncology and neurology pipeline into durable, diversified revenue streams. Key uncertainties include regulatory and reimbursement changes, competition from larger players, and the challenge of moving deeper into therapeutic areas. Overall, the picture is of a financially solid, innovation‑driven company with clear strengths and equally clear execution and concentration risks to monitor.

NEWS

November 10, 2025 · 3:29 PM UTC

Investors who lost money on Lantheus Holdings, Inc. (LNTH) should contact The Gross Law Firm about pending Class Action - LNTH

Read more

November 10, 2025 · 12:20 PM UTC

Portnoy Law Firm Announces Class Action on Behalf of Lantheus Holdings, Inc. Investors

Read more

November 10, 2025 · 11:20 AM UTC

LNTH FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Announces that Lantheus Investors Have Opportunity to Lead Class Action Lawsuit

Read more

November 10, 2025 · 10:00 AM UTC

LNTH Investors Have Opportunity to Lead Lantheus Holdings, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Read more

November 10, 2025 · 8:45 AM UTC

Investors who lost money on Lantheus Holdings, Inc.(LNTH) should contact The Gross Law Firm about pending Class Action - LNTH

Read more